PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor[1].
PD-1-IN-24 (compound 1, 15mg/kg, PO, BID) exhibits TGI(%) of 19.96% in the subcutaneous 4T1 murine breast cancer model in BALB/c mice[1].PD-1-IN-24 (compound 1, 15mg/kg, PO, BID) dose-dependently inhibits tumor growth in the Bl6F10 models with TGI% of 35.59% (30 mg/kg), 38.87% (60 mg/kg) and 47.35% (120 mg/kg), respectively[1].
[1]. Wang, Yuguang, et al. Combination of small molecule inhibitor of the PD-1/PD-L1 interaction and anti-PD-1 antibody for treatment of cancer. Patent WO 2021052386.